Can you take Aldesleukin with Panamax?

The acetaminophen in Panamax has a major potential interaction with Alcoholism.

Chronic alcohol abusers may be at increased risk of hepatotoxicity during treatment with acetaminophen (APAP). Severe liver injury, including cases of acute liver failure resulting in liver transplant and death, has been reported in patients using acetaminophen. Therapy with acetaminophen should be administered cautiously, if at all, in patients who consume three or more alcoholic drinks a day. In general, patients should avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure. They should also be advised to seek medical attention if they experience signs and symptoms of liver injury such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice.

Aldesleukin has a major potential interaction with Autoimmune Disorders.

Aldesleukin may exacerbate existing or activate quiescent autoimmune disease. Therapy with aldesleukin should be administered cautiously in patients with autoimmune diseases.

Aldesleukin has a major potential interaction with Bleeding Disorder.

Aldesleukin induces myelosuppression, primarily thrombocytopenia and anemia. Leukopenia has been reported. Therapy with aldesleukin should be administered cautiously in patients with compromised bone marrow reserve. Clinical monitoring of hematopoietic function is recommended. Subsequent treatment with aldesleukin is contraindicated in patients requiring surgery for GI bleeding or in those patients with bowel ischemia/perforation.

Aldesleukin has a major potential interaction with Bone Marrow Depression/Low Blood Counts.

Aldesleukin induces myelosuppression, primarily thrombocytopenia and anemia. Leukopenia has been reported. Therapy with aldesleukin should be administered cautiously in patients with compromised bone marrow reserve. Clinical monitoring of hematopoietic function is recommended. Subsequent treatment with aldesleukin is contraindicated in patients requiring surgery for GI bleeding or in those patients with bowel ischemia/perforation.

Aldesleukin has a major potential interaction with Cardiovascular Conditions and Disorders.

The use of aldesleukin is contraindicated in patients with abnormal cardiac function as indicated by a thallium stress test. Therapy with aldesleukin should be administered with extreme caution in patients with a normal thallium stress test who have a history of cardiac disease. Close clinical monitoring of cardiac function is required. When adverse events occur that require dosage modification, dosages should be withheld rather than reduced . Subsequent treatment with aldesleukin is contraindicated in patients with sustained ventricular tachycardia, rhythm disturbances uncontrolled or unresponsive to management, recurrent chest pain with ECG changes consistent with angina or myocardial infarction, or pericardial tamponade.

The acetaminophen in Panamax has a major potential interaction with Dehydration.

Acetaminophen is contraindicated in patients with severe hepatic impairment or severe active liver disease. Patients with hepatic impairment may be at increased risk of toxicity. Severe liver injury, including cases of acute liver failure and death, have been reported in patients using this drug. Clinical monitoring of hepatic function is recommended. Caution is advised if using acetaminophen in patients with chronic malnutrition or severe hypovolemia. Instruct patients to avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure.

Aldesleukin has a moderate potential interaction with Depression.

Mental status changes such as lethargy, somnolence, depression, confusion or agitation were reported in over 70% of patients administered aldesleukin. Therapy with aldesleukin should be administered cautiously to patients with or predisposition to altered mental status. When adverse events occur that require dosage modification, dosages should be withheld rather than reduced. Clinical monitoring of mental status is recommended.

Aldesleukin has a major potential interaction with Fluid Retention.

Aldesleukin can cause Capillary Leak Syndrome resulting in ascites or pulmonary edema. Administration of IV fluids may be necessary to maintain organ perfusion and blood pressure. Aldesleukin should be administered cautiously in patients with fixed fluid requirements and/or those adversely affected by fluid overload.

Aldesleukin has a major potential interaction with Gastrointestinal Perforation.

Aldesleukin induces myelosuppression, primarily thrombocytopenia and anemia. Leukopenia has been reported. Therapy with aldesleukin should be administered cautiously in patients with compromised bone marrow reserve. Clinical monitoring of hematopoietic function is recommended. Subsequent treatment with aldesleukin is contraindicated in patients requiring surgery for GI bleeding or in those patients with bowel ischemia/perforation.

Aldesleukin has a major potential interaction with Hypotension.

Hypotension, primarily associated with capillary leak syndrome, has been reported in 85% of patients administered aldesleukin. Seventy-one percent of patients with hypotension required pressor management. Therapy with aldesleukin should be administered cautiously in patients predisposed to hypotension.

Aldesleukin has a major potential interaction with Infection.

The use of aldesleukin may be contraindicated in patients with infections, particularly bacterial diseases. Aldesleukin can interfere with neutrophil chemotaxis and increase the risk of disseminated infections, including bacterial endocarditis and sepsis. Therefore, preexisting bacterial infections should be adequately treated prior to initiation of aldesleukin therapy. Close clinical monitoring of hematopoietic function is recommended during therapy. Since there is increasing evidence that neutrophils may also play important roles in viral and other infections, it may be reasonable in some cases to defer aldesleukin treatment in patients with active nonbacterial infections.

Aldesleukin has a major potential interaction with Liver Disease.

Hepatotoxicity such as elevated bilirubin, transaminase and alkaline phosphatase levels have been reported in over 55% of patients administered aldesleukin. Hepatotoxicity is generally reversible, however, hepatic failure resulting in death has been reported. Therapy with aldesleukin should be administered cautiously in patients with compromised hepatic function. When adverse events occur that require dosage modification, dosages should be withheld rather than reduced. Clinical monitoring of hepatic function is recommended.

The acetaminophen in Panamax has a major potential interaction with Liver Disease.

Acetaminophen is contraindicated in patients with severe hepatic impairment or severe active liver disease. Patients with hepatic impairment may be at increased risk of toxicity. Severe liver injury, including cases of acute liver failure and death, have been reported in patients using this drug. Clinical monitoring of hepatic function is recommended. Caution is advised if using acetaminophen in patients with chronic malnutrition or severe hypovolemia. Instruct patients to avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure.

The acetaminophen in Panamax has a major potential interaction with Malnourishment.

Acetaminophen is contraindicated in patients with severe hepatic impairment or severe active liver disease. Patients with hepatic impairment may be at increased risk of toxicity. Severe liver injury, including cases of acute liver failure and death, have been reported in patients using this drug. Clinical monitoring of hepatic function is recommended. Caution is advised if using acetaminophen in patients with chronic malnutrition or severe hypovolemia. Instruct patients to avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure.

Aldesleukin has a major potential interaction with Organ Transplant.

The use of aldesleukin is contraindicated in patients with allograft organ transplants. Aldesleukin possesses immunoregulatory properties that may increase the risk of organ rejection, including enhancement of lymphocyte mitogenesis and cytotoxicity and induction of killer cell activity.

The acetaminophen in Panamax has a moderate potential interaction with Phenylketonuria.

Several oral acetaminophen and acetaminophen-combination products, particularly flavored chewable tablets, contain the artificial sweetener, aspartame (NutraSweet). Aspartame is converted to phenylalanine in the gastrointestinal tract following ingestion. Chewable and effervescent formulations of acetaminophen products may also contain phenylalanine. The aspartame/phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).

Aldesleukin has a moderate potential interaction with Psychosis.

Mental status changes such as lethargy, somnolence, depression, confusion or agitation were reported in over 70% of patients administered aldesleukin. Therapy with aldesleukin should be administered cautiously to patients with or predisposition to altered mental status. When adverse events occur that require dosage modification, dosages should be withheld rather than reduced. Clinical monitoring of mental status is recommended.

Aldesleukin has a major potential interaction with Pulmonary Impairment.

The use of aldesleukin should be restricted to patients with adequate ventilatory function (baseline FEV1 > 2 L or >= 75% of the predicted value based on height and age). Extreme caution should be used in treating patients with normal test results but have a history of pulmonary disease. Pulmonary congestion and dyspnea have been reported in over 50% of patients receiving the recommended dosage of aldesleukin. Respiratory adverse effects are often associated with the capillary leak syndrome induced by aldesleukin and may also include pulmonary edema, respiratory failure requiring intubation, tachypnea, pleural effusion, wheezing, apnea, pneumothorax, hemoptysis, respiratory arrest, and pulmonary emboli. During therapy, pulmonary function should be monitored regularly by clinical examination, assessment of vital signs and pulse oximetry, and arterial blood gas determinations as needed. When toxicities occur that require a dosage modification, doses should be withheld rather than reduced. Subsequent treatment with aldesleukin is contraindicated in patients who develop respiratory failure requiring intubation for longer than 72 hours.

Aldesleukin has a major potential interaction with Renal Dysfunction.

Renal toxicity such as oliguria/anuria and elevated BUN and serum creatinine has been reported in > 60% of patients during aldesleukin therapy. Renal toxicity is generally reversible, however, patients with renal impairment are at increased risk for more severe and prolonged renal dysfunction. Therapy with aldesleukin should be administered cautiously in patients with compromised renal function. Clinical monitoring of renal function is recommended. When adverse events occur that require dosage modification, dosages should be withheld rather than reduced. Subsequent treatment with aldesleukin is contraindicated in patients experiencing renal dysfunction that requires greater than seventy-two hours of dialysis.

Aldesleukin has a major potential interaction with Seizures.

Aldesleukin can induce seizures. Therapy with aldesleukin should be administered with extreme caution in patients with or predisposition to seizure disorders. When adverse events occur that require dosage modification, dosages should be withheld rather than reduced . Subsequent treatment with aldesleukin is contraindicated in patients with repetitive or difficult to control seizures.